Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vismax
- Development stage
- Phase 4
- Lead developer
- Pharma Innova
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Vismax is a preservative-free ophthalmic solution containing 0.28% sodium hyaluronate, developed for the treatment of moderate to severe dry eye disease. Sodium hyaluronate is a high-molecular-weight polysaccharide that acts as a lubricant and viscoelastic agent, mimicking the properties of natural tears to improve ocular surface hydration and stability. By binding to water and adhering to the corneal epithelium, it increases tear film breakup time (TBUT) and reduces ocular surface damage. The Department of Medical Services of the Ministry of Public Health of Thailand has evaluated its efficacy and safety in comparison to other concentrations of sodium hyaluronate, such as 0.18% formulations.
- Brand names
- Vismax
- Other names
- 0.28% Sodium Hyaluronate0.28% preservative-free sodium hyaluronate
Beyond the preview
Go deeper on Vismax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vismax.